Denali's Hunter Syndrome Drug Sells $17.8 Million In Quarter, But A $194.0 Million Voucher Sale Made The Profit

Denali expects fourth-quarter AVLAYAH sales of $30.0 million to $32.0 million, while operating expenses ran $144.5 million.

Share
Denali's Hunter Syndrome Drug Sells $17.8 Million In Quarter, But A $194.0 Million Voucher Sale Made The Profit

Denali Therapeutics, which develops drugs designed to carry large molecules across the blood-brain barrier, reported $17.8 million in third-quarter net sales of its Hunter syndrome drug AVLAYAH, but a one-time $194.0 million net gain on selling a Priority Review Voucher, not the drug, produced the quarter's profit. The company issued the results Tuesday after the market closed.

A profit built on a voucher

Net income was $70.1 million, against a net loss of $126.9 million in the third quarter of 2025. Without the voucher gain, the business still lost money from operations: the loss was $126.8 million on $144.5 million of operating expenses.

Research and development cost $106.1 million, up from $102.0 million a year earlier. Selling, general and administrative expenses were $37.5 million, up from $35.5 million, which the company tied mainly to higher commercial and medical affairs costs for the launch.

For the first nine months, Denali still posted a net loss of $185.9 million. Cash, cash equivalents and marketable securities were about $1.0 billion as of September 30. Shares closed at $19.45 on Tuesday, before the results came out.

AVLAYAH's second full quarter

AVLAYAH won FDA accelerated approval in March 2026 for neurologic manifestations of Hunter syndrome. Denali says it is the first approved medicine to use the transferrin receptor to cross the blood-brain barrier.

Fourth-quarter net product revenue is expected to be $30.0 million to $32.0 million. Coverage now exceeds 70% of U.S. commercial lives, up from more than 50% in the prior quarter, and 20 state Medicaid programs have published coverage. A permanent billing code took effect October 1.

CEO Ryan Watts said families and physicians are telling the company that AVLAYAH is "making a difference for children with Hunter syndrome." Enrollment in the confirmatory COMPASS study is complete at 65 participants, with data expected in the first half of 2028.

Sanfilippo drug is next in line

Denali wants its delivery platform to carry a second product, zafinofusp alfa, for Sanfilippo syndrome type A. It plans to file for accelerated approval in 2027. Preliminary data showed an 80% mean reduction in cerebrospinal fluid heparan sulfate at week 49, and more data are planned for a medical congress in the first quarter of 2027.

Five TransportVehicle programs are expected to produce data in 2027, including Alzheimer's, frontotemporal dementia and Pompe disease candidates. Denali's conference call was set for 4:30 p.m. ET Tuesday, and it presents at the Stifel healthcare conference November 10-12.

The next test is the fourth quarter, when Denali has guided to $30.0 million to $32.0 million in AVLAYAH sales against a quarterly cost base of more than $144 million.

Sources